Bone Biologics (NASDAQ:BBLG) Stock Rating Upgraded by Wall Street Zen

Bone Biologics (NASDAQ:BBLG) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Bone Biologics Stock Performance

Bone Biologics stock opened at $2.31 on Friday. Bone Biologics has a 1 year low of $2.03 and a 1 year high of $16.50. The business has a 50-day moving average of $2.69 and a 200-day moving average of $4.05.

Bone Biologics (NASDAQ:BBLG) last posted its earnings results on Thursday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.75). On average, analysts anticipate that Bone Biologics will post -5 earnings per share for the current fiscal year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.